D. Western Therapeutics Institute's (TYO:4576) licensee, Kowa Company, has completed subject dosing in a global Phase III clinical trial for K-321, according to its Tokyo bourse filing on Friday.
K-321 is an ophthalmic solution containing ripasudil hydrochloride hydrate, targeting Fuchs endothelial corneal dystrophy.
The trial, conducted across multiple regions including the U.S. and Europe, evaluates the drug's efficacy and safety post-surgery compared to a placebo, with follow-up observations set to conclude by March 2026.
This milestone follows the earlier completion of another Phase III trial, marking progress toward addressing a condition currently reliant on corneal transplantation.
The development aligns with Kowa's broader strategy to expand ripasudil's applications, though it does not impact the fiscal 2025 earnings forecast.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。